Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma

BACKGROUND: The epidermal growth factor receptor (EGFR)-targeted therapies have been tested in the clinic as treatments for head and neck squamous cell carcinoma (HNSCC). Owing to intrinsic or acquired resistance, EGFR-targeted therapies often lead to a low response rate and treatment failure. Inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hailong, Jin, Shufang, Yang, Wenyi, Zhou, Ge, Zhao, Mei, Fang, Sijie, Zhang, Zhiyuan, Hu, Jingzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830595/
https://www.ncbi.nlm.nih.gov/pubmed/29348488
http://dx.doi.org/10.1038/bjc.2017.442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830595/
https://www.ncbi.nlm.nih.gov/pubmed/29348488
http://dx.doi.org/10.1038/bjc.2017.442

Ejemplares similares